UY31466A1 - MONOCLONAL ANTIBODIES THAT JOIN THE HGM-CSF AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM - Google Patents
MONOCLONAL ANTIBODIES THAT JOIN THE HGM-CSF AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEMInfo
- Publication number
- UY31466A1 UY31466A1 UY31466A UY31466A UY31466A1 UY 31466 A1 UY31466 A1 UY 31466A1 UY 31466 A UY31466 A UY 31466A UY 31466 A UY31466 A UY 31466A UY 31466 A1 UY31466 A1 UY 31466A1
- Authority
- UY
- Uruguay
- Prior art keywords
- hgm
- csf
- monoclonal antibodies
- join
- understand
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000001594 aberrant effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000006386 neutralization reaction Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente revela los anticuerpos monoclonales anti-hGM-CSF y fragmentos de union al antígeno de dichos anticuerpos, con una capacidad de neutralizacion mejorada a la actividad de hGM-CSF. Asimismo, se proporcionan composiciones farmacéuticas que comprenden dicho anticuerpo o fragmento de union al antígeno. La presente invencion es util para el tratamiento de varias enfermedades que están asociadas con la expresion aberrante de hGM-CSFThe present discloses anti-hGM-CSF monoclonal antibodies and antigen binding fragments of said antibodies, with an enhanced neutralization ability to hGM-CSF activity. Also, pharmaceutical compositions comprising said antibody or antigen binding fragment are provided. The present invention is useful for the treatment of various diseases that are associated with the aberrant expression of hGM-CSF
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007294945 | 2007-11-13 | ||
JP2008052471 | 2008-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY31466A1 true UY31466A1 (en) | 2009-07-17 |
Family
ID=40329216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY31466A UY31466A1 (en) | 2007-11-13 | 2008-11-12 | MONOCLONAL ANTIBODIES THAT JOIN THE HGM-CSF AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM |
Country Status (32)
Country | Link |
---|---|
US (2) | US8679502B2 (en) |
EP (3) | EP2535353A1 (en) |
KR (1) | KR20100102108A (en) |
CN (2) | CN101970489B (en) |
AR (1) | AR069290A1 (en) |
AU (1) | AU2008321429A1 (en) |
BR (1) | BRPI0820530A2 (en) |
CA (1) | CA2705539A1 (en) |
CL (1) | CL2008003361A1 (en) |
CO (1) | CO6382188A2 (en) |
DK (1) | DK2215119T3 (en) |
EC (1) | ECSP10010251A (en) |
ES (1) | ES2401536T3 (en) |
HK (1) | HK1146729A1 (en) |
HR (1) | HRP20130204T1 (en) |
IL (1) | IL205576A0 (en) |
MA (1) | MA31899B1 (en) |
ME (1) | ME01005B (en) |
MX (1) | MX2010005291A (en) |
NZ (2) | NZ597023A (en) |
PE (1) | PE20091420A1 (en) |
PL (1) | PL2215119T3 (en) |
PT (1) | PT2215119E (en) |
RS (1) | RS52713B (en) |
RU (2) | RU2517596C2 (en) |
SG (1) | SG176499A1 (en) |
SI (1) | SI2215119T1 (en) |
TN (1) | TN2010000210A1 (en) |
TW (2) | TWI434854B (en) |
UY (1) | UY31466A1 (en) |
WO (1) | WO2009064399A1 (en) |
ZA (1) | ZA201003467B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
DE102005035891A1 (en) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
AU2008253608A1 (en) * | 2007-05-23 | 2008-11-27 | Crc For Asthma And Airways Ltd | Neutralizing antibodies |
WO2009062238A1 (en) * | 2007-11-12 | 2009-05-22 | Crc For Asthma And Airways Ltd | Epitope for neutralizing antibodies |
NZ597023A (en) | 2007-11-13 | 2013-07-26 | Boehringer Ingelheim Int | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same |
PE20091730A1 (en) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
UY32030A (en) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "TREATMENT FOR DIABETES IN INAPPROPRIATE PATIENTS FOR THERAPY WITH METFORMIN" |
MX2011002558A (en) | 2008-09-10 | 2011-04-26 | Boehringer Ingelheim Int | Combination therapy for the treatment of diabetes and related conditions. |
EP3056217B1 (en) * | 2008-12-22 | 2021-06-30 | The University of Melbourne | Osteoarthritis treatment |
KR101761324B1 (en) | 2008-12-22 | 2017-07-25 | 더 유니버시티 오브 멜버른 | Pain treatment |
EA201991014A1 (en) | 2010-06-24 | 2019-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | DIABETES TREATMENT |
AR083878A1 (en) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD |
KR20140061379A (en) | 2011-07-06 | 2014-05-21 | 모르포시스 아게 | Therapeutic combinations of anti-cd20 and anti-gm-csf antibodies and uses thereof |
KR20230041086A (en) | 2012-09-20 | 2023-03-23 | 모르포시스 아게 | Treatment for rheumatoid arthritis |
AR093297A1 (en) | 2012-10-31 | 2015-05-27 | Amgen Res (Munich) Gmbh | LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND |
US9833410B2 (en) * | 2012-10-31 | 2017-12-05 | Takeda Gmbh | Lyophilized formulation comprising GM-CSF neutralizing compound |
US20160024200A1 (en) * | 2013-03-14 | 2016-01-28 | John Schrader | Human monoclonal antibodies that neutralize bioactivity of granulocyte macrophage colony-stimulating factor and methods and uses thereof |
BR112016003293A8 (en) | 2013-08-30 | 2022-08-16 | Takeda Gmbh | GM-CSF NEUTRALIZING ANTIBODIES FOR USE IN THE TREATMENT OF RHEUMATOID ARTHRITIS OR AS ANALGESICS |
MX2016014411A (en) | 2014-05-07 | 2017-04-06 | Takeda Gmbh | Liquid formulation comprising gm-csf neutralizing compound. |
CA3036509C (en) * | 2016-09-19 | 2022-10-25 | I-Mab | Anti-gm-csf antibodies and uses thereof |
SG11201912864SA (en) | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
EP3732203A4 (en) * | 2017-12-28 | 2021-12-15 | Nanjing Legend Biotech Co., Ltd. | Antibodies and variants thereof against pd-l1 |
US11655293B2 (en) * | 2018-02-22 | 2023-05-23 | Universitat Zurich | Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT |
EP3623382A1 (en) * | 2018-09-14 | 2020-03-18 | Universität Zürich | Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8624899D0 (en) * | 1986-10-17 | 1986-11-19 | Sandoz Ltd | Monoclonal antibodies |
EP0347057A1 (en) * | 1988-05-31 | 1989-12-20 | Schering Biotech Corporation | Method of treating myeloid leukemias |
HUT63181A (en) | 1989-07-14 | 1993-07-28 | Schering Corp | Process for producing gm-csf antagonists originating from carboxy terminal of gm-csf |
GB8925590D0 (en) * | 1989-11-13 | 1990-01-04 | Central Blood Lab Authority | Monoclonal antibodies |
US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
WO1992008474A2 (en) | 1990-11-20 | 1992-05-29 | The National Heart & Lung Institute | Treatment of lung diseases |
CA2060741A1 (en) | 1991-02-11 | 1992-08-12 | Robert S. Greenfield | Gm-csf inhibiting oligopeptides |
US5833987A (en) * | 1995-06-07 | 1998-11-10 | Trustees Of Dartmouth College | Treatment of T cell mediated autoimmune disorders |
AU6873396A (en) * | 1995-10-16 | 1997-05-07 | Unilever N.V. | A bifunctional or bivalent antibody fragment analogue |
US5662138A (en) * | 1996-06-12 | 1997-09-02 | Wang; Wen-Hsing | Drop head structure |
US7455836B2 (en) * | 2000-05-08 | 2008-11-25 | The University Of Melbourne | Method of treatment and agents useful for same |
PT2281843T (en) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
WO2002024865A2 (en) * | 2000-09-19 | 2002-03-28 | Microbia, Inc. | Modulation of secondary metabolite production by zinc binuclear cluster proteins |
PE20021080A1 (en) | 2001-04-12 | 2003-02-12 | Boehringer Ingelheim Int | A SPECIFIC ANTIBODY FAPO BIBH1 IN THE TREATMENT OF CANCER |
US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
WO2003040341A2 (en) * | 2001-11-07 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-hepatitis a virus antibodies |
ATE509032T1 (en) | 2002-02-13 | 2011-05-15 | Ludwig Inst For Cancer Res Ltd | CHIMERIZED GM-CSF ANTIBODIES |
US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
AR045563A1 (en) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | ANTIBODIES DIRECTED TO M-CSF |
CA2549409C (en) | 2003-12-03 | 2013-10-29 | Neose Technologies, Inc. | Glycopegylated granulocyte colony stimulating factor |
UA89364C2 (en) | 2003-12-03 | 2010-01-25 | Биодженерикс Аг | Granulocyte colony stimulating factor peptide conjugate (g-csf) |
EP1593690B1 (en) | 2004-05-05 | 2009-07-01 | Micromet AG | Preparation of ScFv antibody fragments |
WO2006011353A1 (en) | 2004-07-30 | 2006-02-02 | Thk Co., Ltd. | Thread groove processing method |
SG161292A1 (en) * | 2005-04-18 | 2010-05-27 | Micromet Ag | Antibody neutralizers of human granulocyte macrophage colony stimulating factor |
DK1888643T3 (en) * | 2005-05-18 | 2015-01-05 | Morphosys Ag | Anti-GM-CSF antibodies as well as their uses |
JP4736037B2 (en) * | 2005-10-26 | 2011-07-27 | 株式会社イーベック | Human monoclonal antibody binding to human GM-CSF and antigen-binding portion thereof |
CN101501070B (en) * | 2006-02-08 | 2013-12-25 | 诺福泰克公司 | Antigenic GM-CSF peptides and antibodies to GM-CSF |
US8398972B2 (en) * | 2006-11-21 | 2013-03-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating dementia using a GM-CSF antagonist |
AU2007323541B2 (en) | 2006-11-21 | 2012-01-19 | Kalobios Pharmaceuticals, Inc. | Methods of treating chronic inflammatory diseases using a GM-CSF antagonist |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
NZ597023A (en) | 2007-11-13 | 2013-07-26 | Boehringer Ingelheim Int | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same |
-
2008
- 2008-11-12 NZ NZ597023A patent/NZ597023A/en not_active IP Right Cessation
- 2008-11-12 US US12/681,396 patent/US8679502B2/en active Active
- 2008-11-12 ME MEP-2010-89A patent/ME01005B/en unknown
- 2008-11-12 PE PE2008001912A patent/PE20091420A1/en not_active Application Discontinuation
- 2008-11-12 DK DK08848696.4T patent/DK2215119T3/en active
- 2008-11-12 TW TW097143709A patent/TWI434854B/en not_active IP Right Cessation
- 2008-11-12 SI SI200830911T patent/SI2215119T1/en unknown
- 2008-11-12 EP EP12181684A patent/EP2535353A1/en not_active Withdrawn
- 2008-11-12 ES ES08848696T patent/ES2401536T3/en active Active
- 2008-11-12 NZ NZ586027A patent/NZ586027A/en not_active IP Right Cessation
- 2008-11-12 AR ARP080104932A patent/AR069290A1/en active Pending
- 2008-11-12 PT PT88486964T patent/PT2215119E/en unknown
- 2008-11-12 SG SG2011085453A patent/SG176499A1/en unknown
- 2008-11-12 EP EP08848696A patent/EP2215119B1/en active Active
- 2008-11-12 BR BRPI0820530-2A patent/BRPI0820530A2/en not_active IP Right Cessation
- 2008-11-12 AU AU2008321429A patent/AU2008321429A1/en not_active Abandoned
- 2008-11-12 RS RS20130035A patent/RS52713B/en unknown
- 2008-11-12 KR KR1020107012568A patent/KR20100102108A/en not_active Application Discontinuation
- 2008-11-12 CN CN200880124664.1A patent/CN101970489B/en not_active Expired - Fee Related
- 2008-11-12 TW TW100141459A patent/TW201206955A/en unknown
- 2008-11-12 PL PL08848696T patent/PL2215119T3/en unknown
- 2008-11-12 RU RU2010123693/10A patent/RU2517596C2/en not_active IP Right Cessation
- 2008-11-12 EP EP12192975A patent/EP2559706A1/en not_active Withdrawn
- 2008-11-12 WO PCT/US2008/012680 patent/WO2009064399A1/en active Application Filing
- 2008-11-12 CA CA2705539A patent/CA2705539A1/en not_active Abandoned
- 2008-11-12 MX MX2010005291A patent/MX2010005291A/en active IP Right Grant
- 2008-11-12 CL CL2008003361A patent/CL2008003361A1/en unknown
- 2008-11-12 CN CN201410203384.7A patent/CN104072613A/en active Pending
- 2008-11-12 UY UY31466A patent/UY31466A1/en not_active Application Discontinuation
-
2010
- 2010-05-06 IL IL205576A patent/IL205576A0/en unknown
- 2010-05-12 TN TN2010000210A patent/TN2010000210A1/en unknown
- 2010-05-17 ZA ZA2010/03467A patent/ZA201003467B/en unknown
- 2010-06-03 MA MA32889A patent/MA31899B1/en unknown
- 2010-06-11 CO CO10070935A patent/CO6382188A2/en active IP Right Grant
- 2010-06-14 EC EC2010010251A patent/ECSP10010251A/en unknown
-
2011
- 2011-01-27 HK HK11100827.6A patent/HK1146729A1/en not_active IP Right Cessation
-
2013
- 2013-03-08 HR HRP20130204AT patent/HRP20130204T1/en unknown
- 2013-09-09 RU RU2013141223/10A patent/RU2013141223A/en not_active Application Discontinuation
-
2014
- 2014-01-28 US US14/166,803 patent/US20140205611A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY31466A1 (en) | MONOCLONAL ANTIBODIES THAT JOIN THE HGM-CSF AND THE MEDICAL COMPOSITIONS THAT UNDERSTAND THEM | |
CY1122490T1 (en) | ANTIBODIES TO HUMAN CD38 | |
CY1119454T1 (en) | ANTIBODIES AGAINST CD38 FOR TREATMENT OF MULTIPLE MYELOMA | |
BR112018074155A2 (en) | lag-3 antibody, antigen binding fragment and pharmaceutical application thereof | |
CO6290643A2 (en) | CYCLOPROPYLAMINE DERIVATIVES | |
CY1121148T1 (en) | VEGF / DLL4 CONNECTING FACTORS AND THEIR USES | |
CU20170169A7 (en) | FACTOR ANTIBODIES XI | |
BR112018014615A2 (en) | ror1 antibody compositions and related methods | |
CR20120105A (en) | THERAPEUTIC PROTEINS OF UNION TO DLL4 | |
BR112013004056B8 (en) | HUMAN-PROJECTED AB ANTI-N3PGLU MONOCLONAL ANTIBODIES, THEIR USE AND PHARMACEUTICAL COMPOSITION INCLUDING THEM | |
ECSP19044625A (en) | ANTIBODY-DRUG CONJUGATES FOR ABLATION OF HEMATOPOIETIC STEM CELLS | |
CY1118053T1 (en) | MEDICINAL COMPOSITIONS WITH RESOLUTION IN CEA SOLUTION | |
AR060130A1 (en) | FORMULATION OF AN ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY | |
CR20130624A (en) | PROTEINS OF UNION TO ANTIGEN | |
UA109633C2 (en) | HUMAN ANTIBODY AGAINST TISSUE FACTOR | |
BR112019024654A2 (en) | binding protein nkg2d, cd16 and ror1 or ror2 | |
PA8849001A1 (en) | C-MET ANTIBODIES | |
ECSP14001260A (en) | BI-SPECIFIC IMMUNOLIGANTS TARGETED AGAINST TNF AND IL-17 CROSS REFERENCE TO RELATED REQUESTS | |
AR059922A1 (en) | HUMANIZED MONOCLONAL ANTIBODIES FOR THE GROWTH FACTOR OF HEPATOCITS | |
CL2008002923A1 (en) | Human monoclonal antibody isolated because it binds to human mesothelin; composition comprising said antibody; conjugate between antibody and therapeutic agent; nucleic acid molecule that encodes the antibody; use to prepare a drug to treat cancer. | |
AR057807A1 (en) | ANTI-CD3 ANTIBODY FORMULATIONS | |
AR095666A1 (en) | CONJUGATES OF DRUGS WITH ANTIBODIES | |
UY32061A (en) | HUMAN ANTIBODIES FOR HUMAN RANKL | |
AR062268A1 (en) | BINDING AGENTS DIRECTED TO PDGFR-ALFA AND ITS USES | |
CY1120803T1 (en) | ANTIGONE BINDING PROTEINS SPECIFIC FOR THE STRUCTURE OF STARCH |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20171017 |